person · Reporting owner

Kaye Edward M. MD

Disclosed activity across 4 companies

Tapewire entity: 22218
SEC CIK: 0001522780

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CYTOKINETICS INCCYTK · Entity 3528	Director	July 15, 2026	July 16, 2026
Sarepta Therapeutics, Inc.SRPT · Entity 4426	Director	August 03, 2017	August 07, 2017
Stoke Therapeutics, Inc.STOK · Entity 1723	Director	August 14, 2026	August 19, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CYTOKINETICS INC

Report date July 15, 2026 · Filed July 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,434	Reported balance After 2026-07-15 transaction · row 1 1 source row Row 1 · 2026-07-15 · Grant · Acquired 151 · Balance 10,434 F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

Sarepta Therapeutics, Inc.

Report date August 03, 2017 · Filed August 07, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	71,229	Ending reported balance After 2017-08-03 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2017-08-03 · Exercise / conversion · Acquired 35,461 · Balance 87,932 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2017-08-03 · Tax withholding · Disposed 16,703 · Balance 71,229 F2: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2017-08-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-08-03 · Exercise / conversion · Disposed 35,461 · Balance 0 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017.

F3: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units.

Stoke Therapeutics, Inc.

Report date August 14, 2026 · Filed August 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	124,557	Ending reported balance After 2026-08-18 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-08-14 · Exercise / conversion · Acquired 26,250 · Balance 137,124 Row 2 · 2026-08-18 · Sale · Disposed 11,930 · Balance 125,194 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Row 3 · 2026-08-18 · Sale · Disposed 637 · Balance 124,557 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.
Performance Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-08-14	Direct	0	Reported balance After 2026-08-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-08-14 · Exercise / conversion · Disposed 26,250 · Balance 0 F4: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F5: Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.

F4: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F5: Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Avidity Biosciences, Inc.

Report date February 27, 2026 · Filed February 27, 2026

Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-02-27 transaction · row 1 1 source row Row 1 · 2026-02-27 · Disposition to issuer · Disposed 6,692 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.62 · Expires 2035-06-09	Direct	Reported balance After 2026-02-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-27 · Disposition to issuer · Disposed 10,034 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.96 · Expires 2034-06-12	Direct	Reported balance After 2026-02-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-27 · Disposition to issuer · Disposed 13,489 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.48 · Expires 2033-06-14	Direct	Reported balance After 2026-02-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-02-27 · Disposition to issuer · Disposed 22,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.03 · Expires 2032-06-14	Direct	Reported balance After 2026-02-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-02-27 · Disposition to issuer · Disposed 22,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2031-06-15	Direct	Reported balance After 2026-02-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-02-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.82 · Expires 2030-05-14	Direct	Reported balance After 2026-02-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-02-27 · Disposition to issuer · Disposed 11,323 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2029-08-27	Direct	Reported balance After 2026-02-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-02-27 · Disposition to issuer · Disposed 9,534 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.

F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 06, 2025 Filed Oct 6, 2025 20:27 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	6,757	$60.00	$405,420.00	Disclosure SEC source: 0001061983-25-000008 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,778 Read SEC document
October 03, 2025 Filed Oct 7, 2025 20:26 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	SaleCommon Stock	42,461	$25.09	$1,065,206.37	Disclosure SEC source: 0001522780-25-000004 · form4-10072025_081055.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,124 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 30, 2025 Filed Sep 30, 2025 20:33 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	6,695	$55.08	$368,760.60	Disclosure SEC source: 0001061983-25-000006 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,535 Read SEC document
September 04, 2025 Filed Sep 5, 2025 20:10 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Disposition to issuerRestricted Stock Units · Derivative	144,000	$0.00	$0.00	Disclosure SEC source: 0001415889-25-023792 · form4-09052025_080918.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 144,000 shares Expires 2029-03-20 F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · kind: The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The entire equity award was canceled for no consideration by mutual agreement of the reporting person and the Issuer. F4 · price: The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The entire equity award was canceled for no consideration by mutual agreement of the reporting person and the Issuer. F5 · derivative.exercise_date: Pursuant to the terms under which it was granted, the award was scheduled to vest as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document
September 04, 2025 Filed Sep 5, 2025 20:10 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	178,500	$0.00 Strike: $8.33	$0.00	Disclosure SEC source: 0001415889-25-023792 · form4-09052025_080918.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 178,500 shares Expires 2035-03-19 F1 · kind: The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The equity award was partially canceled for no consideration by mutual agreement of the reporting person and the Issuer. F1 · price: The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The equity award was partially canceled for no consideration by mutual agreement of the reporting person and the Issuer. F2 · derivative.exercise_date: The option began vesting on April 15, 2025. Pursuant to the terms of the initial grant, the original number of shares subject to the option vests in ratable increments monthly and the option shall be fully vested on December 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document
September 03, 2025 Filed Sep 3, 2025 21:51 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	SaleCommon Stock	45,996	$20.13	$925,858.08	Disclosure SEC source: 0001415889-25-023590 · form4-09032025_090950.xml · nonDerivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,585 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. Read SEC document
September 02, 2025 Filed Sep 2, 2025 20:41 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	6,756	$50.00	$337,800.00	Disclosure SEC source: 0001127602-25-021074 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,230 Read SEC document
September 02, 2025 Filed Sep 3, 2025 21:51 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	SaleCommon Stock	14,860	$20.14	$299,259.60	Disclosure SEC source: 0001415889-25-023590 · form4-09032025_090950.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,581 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document
August 29, 2025 Filed Sep 3, 2025 21:51 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	SaleCommon Stock	1,029	$20.00	$20,580.00	Disclosure SEC source: 0001415889-25-023590 · form4-09032025_090950.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,441 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024. Read SEC document
August 18, 2025 Filed Aug 20, 2025 20:12 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	SaleCommon Stock	12,126	$18.24	$221,153.99	Disclosure SEC source: 0001415889-25-022441 · form4-08202025_080810.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,470 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.50 per share, inclusive. Read SEC document
August 14, 2025 Filed Aug 19, 2025 00:23 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionPerformance Stock Units · Derivative	26,250	$0.00	$0.00	Disclosure SEC source: 0001415889-25-022225 · form4-08192025_120819.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2026-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document
August 14, 2025 Filed Aug 19, 2025 00:23 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantPerformance Stock Units · Derivative	52,500	$0.00	$0.00	Disclosure SEC source: 0001415889-25-022225 · form4-08192025_120819.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2026-08-14 F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date. F3 · derivative.exercise_date: Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document
August 14, 2025 Filed Aug 19, 2025 00:23 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionCommon Stock	26,250	$0.00	$0.00	Disclosure SEC source: 0001415889-25-022225 · form4-08192025_120819.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 15, 2025 Filed Jul 16, 2025 21:43 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	328	$38.01	$12,467.28	Disclosure SEC source: 0001127602-25-019288 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,986 F1 · kind: Director equity in lieu of cash retainer program. Read SEC document
June 10, 2025 Filed Jun 12, 2025 22:37 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	GrantStock Option (Right to Buy) · Derivative	10,034	$0.00 Strike: $33.62	$0.00	Disclosure SEC source: 0001599901-25-000125 · wk-form4_1749767841.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,034 Underlying: Common Stock · 10,034 shares Expires 2035-06-09 F2 · derivative.exercise_date: This option shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document
June 10, 2025 Filed Jun 12, 2025 22:37 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	GrantCommon Stock	6,692	$0.00	$0.00	Disclosure SEC source: 0001599901-25-000125 · wk-form4_1749767841.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,692 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document
June 05, 2025 Filed Jun 5, 2025 20:42 UTC	CYTOKINETICS INC CYTK · Entity 3528	SaleCommon Stock	3,636	$32.10	$116,715.60	Disclosure SEC source: 0001127602-25-016870 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,658 Read SEC document
May 14, 2025 Filed May 14, 2025 23:35 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	10,880	$0.00 Strike: $30.00	$0.00	Disclosure SEC source: 0001127602-25-014360 · form4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,880 Underlying: Common Stock · 10,880 shares Expires 2035-05-13 F2 · kind: Comprised of stock options that will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier to occur of (x) the one-year anniversary of the date of the grant and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. Read SEC document
May 14, 2025 Filed May 14, 2025 23:35 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	7,333	$0.00	$0.00	Disclosure SEC source: 0001127602-25-014360 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,294 F1 · kind: Comprised of restricted stock units ("RSUs") that will vest in one installment on the earlier to occur of (x) the one-year anniversary of the grant date and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. RSUs convert to shares of common stock on a 1:1 basis upon vesting. Read SEC document
April 15, 2025 Filed Apr 16, 2025 20:05 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	324	$38.56	$12,493.44	Disclosure SEC source: 0001127602-25-012114 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,961 F1 · kind: Shares acquired pursuant to Director Stock in lieu of Cash Retainer Program. Read SEC document
March 20, 2025 Filed Mar 20, 2025 22:15 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantRestricted Stock Units · Derivative	144,000	$0.00	$0.00	Disclosure SEC source: 0001415889-25-008711 · form4-03202025_100313.xml · derivative · entry 4 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 144,000 shares Expires 2029-03-20 F5 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The award vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document
March 20, 2025 Filed Mar 20, 2025 22:15 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantEmployee Stock Option (Right to Buy) · Derivative	216,000	$0.00 Strike: $8.33	$0.00	Disclosure SEC source: 0001415889-25-008711 · form4-03202025_100313.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,000 Underlying: Common Stock · 216,000 shares Expires 2035-03-19 F4 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on April 15, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document
March 19, 2025 Filed Mar 20, 2025 22:15 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	SaleCommon Stock	8,907	$8.27	$73,660.89	Disclosure SEC source: 0001415889-25-008711 · form4-03202025_100313.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,346 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.06 to $8.95 per share, inclusive. Read SEC document
March 18, 2025 Filed Mar 20, 2025 22:15 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	SaleCommon Stock	10,382	$8.67	$90,011.94	Disclosure SEC source: 0001415889-25-008711 · form4-03202025_100313.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,253 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.11 to $8.925 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 3. Read SEC document
March 15, 2025 Filed Mar 18, 2025 20:07 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionRestricted Stock Units · Derivative	26,250	$0.00	$0.00	Disclosure SEC source: 0001415889-25-008355 · form4-03182025_080305.xml · derivative · entry 4 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 26,250 shares Expires 2028-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document
March 15, 2025 Filed Mar 18, 2025 20:07 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionRestricted Stock Units · Derivative	35,500	$0.00	$0.00	Disclosure SEC source: 0001415889-25-008355 · form4-03182025_080305.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 35,500 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document
March 15, 2025 Filed Mar 18, 2025 20:07 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionCommon Stock	26,250	$0.00	$0.00	Disclosure SEC source: 0001415889-25-008355 · form4-03182025_080305.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 15, 2025 Filed Mar 18, 2025 20:07 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionCommon Stock	35,500	$0.00	$0.00	Disclosure SEC source: 0001415889-25-008355 · form4-03182025_080305.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:25 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	255	$48.93	$12,477.15	Disclosure SEC source: 0001127602-25-000765 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,637 F1 · kind: Director Stock in Lieu of Cash Retainer Program Read SEC document
December 30, 2024 Filed Jan 2, 2025 21:14 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $0.60	$0.00	Disclosure SEC source: 0001415889-25-000084 · form4-01022025_090156.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 567,801 Underlying: Common Stock · 35,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option became fully vested as of October 17, 2022. Read SEC document
December 30, 2024 Filed Jan 2, 2025 21:14 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionCommon Stock	35,000	$0.60	$21,000.00	Disclosure SEC source: 0001415889-25-000084 · form4-01022025_090156.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 09, 2024 Filed Dec 11, 2024 21:04 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	SaleCommon Stock	6,786	$12.99	$88,158.28	Disclosure SEC source: 0001415889-24-028928 · form4-12112024_091247.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,885 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.13 per share, inclusive. Read SEC document
December 06, 2024 Filed Dec 11, 2024 00:00 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	SaleCommon Stock	6,170	$12.78	$78,837.18	Disclosure SEC source: 0001415889-24-028890 · form4-12112024_121241.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,671 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.93 to $13.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 03, 2024 Filed Dec 5, 2024 21:20 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionPerformance Stock Units · Derivative	26,500	$0.00	$0.00	Disclosure SEC source: 0001415889-24-028397 · form4-12052024_091208.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,500 Underlying: Common Stock · 26,500 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document
December 03, 2024 Filed Dec 5, 2024 21:20 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantPerformance Stock Units · Derivative	53,000	$0.00	$0.00	Disclosure SEC source: 0001415889-24-028397 · form4-12052024_091208.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2025-12-03 F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date. F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document
December 03, 2024 Filed Dec 5, 2024 21:20 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionCommon Stock	26,500	$0.00	$0.00	Disclosure SEC source: 0001415889-24-028397 · form4-12052024_091208.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 03, 2024 Filed Dec 10, 2024 23:59 UTC Amendment	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionPerformance Stock Units · Derivative	26,250	$0.00	$0.00	Disclosure SEC source: 0001415889-24-028889 · form4a-12102024_111228.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document
December 03, 2024 Filed Dec 10, 2024 23:59 UTC Amendment	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantPerformance Stock Units · Derivative	52,500	$0.00	$0.00	Disclosure SEC source: 0001415889-24-028889 · form4a-12102024_111228.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2025-12-03 F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date. F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document
December 03, 2024 Filed Dec 10, 2024 23:59 UTC Amendment	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionCommon Stock	26,250	$0.00	$0.00	Disclosure SEC source: 0001415889-24-028889 · form4a-12102024_111228.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 01, 2024 Filed Dec 3, 2024 21:13 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionRestricted Stock Unit (RSU) · Derivative	21,591	$0.00	$0.00	Disclosure SEC source: 0001415889-24-028070 · form4-12032024_091257.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,317 Underlying: Common Stock · 21,591 shares Expires 2025-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: 21,591 restricted stock units will vest on December 1, 2024 and 4,317 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document
December 01, 2024 Filed Dec 3, 2024 21:13 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionCommon Stock	21,591	$0.00	$0.00	Disclosure SEC source: 0001415889-24-028070 · form4-12032024_091257.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 01, 2024 Filed Dec 4, 2025 01:22 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	Exercise / conversionCommon Stock	4,317	$0.00	$0.00	Disclosure SEC source: 0001522780-25-000008 · form4-12042025_011205.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 01, 2024 Filed Oct 3, 2024 21:26 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	237	$52.60	$12,466.20	Disclosure SEC source: 0001127602-24-025195 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,382 F1 · kind: Stock award in lieu of cash retainer payment. Read SEC document
July 01, 2024 Filed Jul 4, 2024 00:04 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	228	$0.00	$0.00	Disclosure SEC source: 0001127602-24-020148 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,145 F1 · kind: Stock award in lieu of cash retainer payment. Read SEC document
June 13, 2024 Filed Jun 14, 2024 23:09 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	GrantStock Option (Right to Buy) · Derivative	13,489	$0.00 Strike: $39.96	$0.00	Disclosure SEC source: 0001599901-24-000103 · wk-form4_1718406571.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,489 Underlying: Common Stock · 13,489 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option shall vest on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document
May 20, 2024 Filed May 22, 2024 20:17 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	SaleCommon Stock	2,664	$16.05	$42,745.74	Disclosure SEC source: 0001415889-24-014087 · form4-05222024_080510.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,000 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 26, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 20, 2024 Filed May 22, 2024 20:17 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	SaleCommon Stock	39,686	$15.39	$610,783.41	Disclosure SEC source: 0001415889-24-014087 · form4-05222024_080510.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,664 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 26, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 15, 2024 Filed May 16, 2024 22:03 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	3,636	$0.00 Strike: $60.50	$0.00	Disclosure SEC source: 0001127602-24-015721 · form4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,636 Underlying: Common Stock · 3,636 shares Expires 2034-05-15 Read SEC document
May 15, 2024 Filed May 16, 2024 22:03 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	5,600	$0.00	$0.00	Disclosure SEC source: 0001127602-24-015721 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,917 Read SEC document
March 27, 2024 Filed Jun 7, 2024 20:42 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantRestricted Stock Units · Derivative	105,000	$0.00	$0.00	Disclosure SEC source: 0001415889-24-016010 · form4-06072024_080631.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2028-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.